Companies/Umecrine Cognition AB
Follow

Umecrine Cognition AB

Nasdaq First North GM Stockholm (Sweden)

Umecrine Cognition is developing pharmaceuticals against neurological disorders in the central nervous system, CNS that are caused by endogenous CNS-active steroids (neurosteroids).

Sector:
HEALTH CARE
 
Top
News
Notice to attend the Annual General Meeting in Umecrine Cognition AB
17 May 2023 - 08:45
First patient included in Umecrine Cognition’s clinical Phase 2 study of golexanolone in primary biliary cholangitis
17 Apr 2023 - 08:45
Umecrine Cognition secures additional funding to progress its drug development projects
28 Mar 2023 - 08:45
Umecrine Cognition announces Orphan Drug Designation granted by FDA for golexanolone
17 Jan 2023 - 08:45
Umecrine Cognition will attend the JP Morgan 41st Annual Healthcare Conference 2023 in San Francisco
09 Jan 2023 - 08:45
Umecrine Cognition presents data showing improved symptoms in a model of Parkinson’s disease following treatment with golexanolone
03 Jan 2023 - 08:45
Umecrine Cognition presents data showing reversal of fatigue in a model of PBC following treatment with golexanolone
28 Sep 2022 - 08:31
Umecrine Cognition secures funding ahead of Phase 2 study of golexanolone in patients with primary biliary cholangitis
14 Sep 2022 - 11:00
Umecrine Cognition announces the recruitment of Anders Karlsson as new CEO
10 Aug 2022 - 17:31
Notice to attend Extraordinary General Meeting in Umecrine Cognition AB
07 Jul 2022 - 12:00
Umecrine Cognition submits application for Phase 2 clinical trial of golexanolone
19 May 2022 - 08:00
Notice to attend the Annual General Meeting in Umecrine Cognition AB
18 May 2022 - 09:45
Umecrine Cognition completes successful pre-IND meeting with FDA
14 Mar 2022 - 07:59
Umecrine Cognition to present preclinical results showing beneficial effects of golexanolone on neuroinflammation and movement dysfunction
21 Feb 2022 - 07:00
Umecrine Cognition presents data showing a reduction of neuroinflammation following treatment with golexanolone
10 Jan 2022 - 09:00
Umecrine Cognition presents data supporting a new predictive biomarker in patients with primary biliary cholangitis at the AASLD International Liver Meeting 2021
03 Nov 2021 - 08:00
Umecrine Cognition enters collaboration with University College London to increase insights around golexanolone
18 Oct 2021 - 14:00
Umecrine Cognition to present at two scientific conferences on the importance of neurosteroids in cognitive dysfunction associated with liver disease
06 Oct 2021 - 13:00
1
Show

20

Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Umecrine Cognition AB with ticker
Status
Inactive
Currency
SEK
Listing
Sign in to buy
People
Anders Karlsson
CEO
Viktor Drvota
Chairman of the board
Thomas Paul Blackburn
Board member
Bruce Frederic Scharschmidt
Board member
John Öhd
Board member
Carl Torbjörn Bäckström
Board member
Company Details
Sector
HEALTH CARE
Website
Address
Fogdevreten 2
Zip code
171 65
City/district
Solna
Country
Sweden (SE)
Phones
Email
[email protected]
Registration number
556698-3655
LEI code
894500AF89I6QWOX2Q84
First trade date
Registration date
14 Feb 2006
Short name
UMCR

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More